台灣臨床試驗主持人資料庫|TPIDB

問卷

Log In

繁中 EN

TPIDB

TPIDB Outstanding PI

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberAR-DEX-22-03

Completed

2024-01-01 - 2025-12-31

Phase III

Recruiting9

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 24 weeks in participants with eosinophilic asthma (EXHALE-4)

Trial Applicant

WORLDWIDE CLINICAL TRIALS (TAIWAN) CO., LTD.
Sponsor

Areteia Therapeutics, Inc
Trial scale

Multi-Regional Multi-Center
Update

2026/02/01

Investigators and Locations

Principal Investigator Liang-wen Hang 無

China Medical University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Pin-Kuei Fu 無

Taichung Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Pai-Chien Chou 無

Taipei Medical University Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 曾敬閔無

Cheng Hsin General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chau-Chyun Sheu 無

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Zhi Chen 無

Taipei Veterans General Hospital

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 鄭世隆無

Far Eastern Memorial Hospital

Co-Principal Investigator

張晟瑜無
王秉槐無

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Ping-Hung Kuo 無

National Taiwan University Hospital

Co-Principal Investigator

阮聖元無
黃俊凱無

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Po-Hao Feng

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

eosinophilic asthma (EXHALE-4)

Objectives

To evaluate the efficacy of dexpramipexole on pulmonary function

Test Drug

tabltes

Active Ingredient

Dexpramipexole

Dosage Form

110

Dosage

75 mg/ 150 mg

Endpoints

To evaluate the efficacy of dexpramipexole on pulmonary function.

Inclution Criteria

To be eligible to participate in this study, candidates must meet the following
eligibility criteria at Screening Visit 1 or at the time point specified in the individual
eligibility criterion listed below:
1. Signed informed consent form and assent form, as appropriate.
2. Male or female ≥12 years of age at Screening Visit 1. Sites in Poland will
only include participants aged ≥18 years.

Exclusion Criteria

Study participant candidates will be excluded from study entry if any of the
following exclusion criteria exist at Screening Visit 1 or at the timepoint specified in
the individual criterion listed below:

The Estimated Number of Participants

Taiwan

40 participants
Global

550 participants